4.5 Article

Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases

Journal

HUMAN MOLECULAR GENETICS
Volume 31, Issue 17, Pages 3001-3011

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddac089

Keywords

-

Funding

  1. European Research Council
  2. National Institute for Health and Care research (NIHR)
  3. National Institute for Health and Care research (NIHR) [Cambridge NIHR Biomedical Research Centre] [BRC-1215-20014]
  4. Cancer Research UK Cambridge Cancer Centre [SSAG/085]
  5. VHL UK/Ireland
  6. Cancer Research UK [C1298/A8362, C69256/A30194, A29911]
  7. Wellcome Trust [214388]
  8. Medical Research Council
  9. NIHR Oxford Biomedical Research Centre (Molecular Diagnostics Theme)
  10. UK Medical Research Council [MR/V033077/1]
  11. Rosetrees Trust [A2437, A2204]
  12. Francis Crick Institute from Cancer Research UK [FC10988]
  13. Francis Crick Institute from UK Medical Research Council [FC10988]
  14. Francis Crick Institute from Wellcome Trust [FC10988]
  15. NIHR BRC at the Royal Marsden Hospital
  16. NIHR BRC at the Institute of Cancer Research [A109]
  17. Royal Marsden Cancer Charity
  18. Ventana Medical Systems Inc [10467, 10530]
  19. National Institute of Health [U01 CA247439]
  20. Melanoma Research Alliance [686061]

Ask authors/readers for more resources

In unselected RCC patients, approximately 6% carry germline variants that require further follow-up analysis. Expanding the genomic panel for RCC susceptibility gene testing can improve diagnostic yield.
Renal cell carcinoma (RCC) occurs in a number of cancer predisposition syndromes, but the genetic architecture of susceptibility to RCC is not well defined. We investigated the frequency of pathogenic and likely pathogenic (P/LP) germline variants in cancer susceptibility genes (CSGs) within a large series of unselected RCC participants. Whole-genome sequencing data on 1336 RCC participants and 5834 controls recruited to the UK 100 000 Genomes Project, a nationwide multicentre study, was analyzed to identify rare P/LP short variants (single nucleotide variants and insertions/deletions ranging from 1 to 50 base pairs) and structural variants in 121 CSGs. Among 1336 RCC participants [mean: 61.3 years (+/- 12 SD), range: 13-88 years; 64% male], 85 participants [6.4%; 95% CI (5.1, 7.8)] had one or more P/LP germline variant in a wider range of CSGs than previously recognized. A further 64 intragenic variants in CSGs previously associated with RCC were classified as a variant of uncertain significance (VUS) (24 'hot VUSs') and were considered to be of potential clinical relevance as further evaluation might results in their reclassification. Most patients with P variants in well-established CSGs known to predispose to renal cell carcinoma (RCC-CSGs) were aged CHEK2 variants in European RCC participants compared with the healthy European controls (P = 0.0019). Approximately, 6% of the patients with RCC unselected for family history have a germline variant requiring additional follow-up analysis. To improve diagnostic yield, we suggest expanding the panel of RCC-CSGs tested to include CHEK2 and all SDHx subunits and raising the eligibility criteria for age-based testing.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available